AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by WCM Investment Management LLC

WCM Investment Management LLC trimmed its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 11.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 191,801 shares of the medical device company’s stock after selling 23,785 shares during the period. WCM Investment Management LLC owned about 0.39% of AtriCure worth $5,802,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Arcadia Investment Management Corp MI acquired a new position in shares of AtriCure during the 3rd quarter worth $28,000. Heck Capital Advisors LLC acquired a new position in AtriCure during the fourth quarter worth about $60,000. KBC Group NV raised its position in AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after acquiring an additional 932 shares during the last quarter. R Squared Ltd purchased a new stake in shares of AtriCure in the fourth quarter valued at about $89,000. Finally, nVerses Capital LLC increased its stake in shares of AtriCure by 733.3% during the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock worth $140,000 after purchasing an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ATRC shares. UBS Group upped their target price on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Needham & Company LLC increased their price objective on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $40.00 target price on shares of AtriCure in a research note on Tuesday, December 17th. Oppenheimer raised their price target on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research report on Monday, December 9th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.38.

AtriCure Price Performance

ATRC opened at $41.00 on Monday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The company’s 50 day simple moving average is $35.19 and its 200 day simple moving average is $30.78. The stock has a market capitalization of $2.00 billion, a PE ratio of -49.40 and a beta of 1.46. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.